Jotbody is on the cutting edge of single domain antibody (sdAb, also called nanobody) discovery, production and applications. Jotbody is dedicated to offering sdAb discovery services and sdAb-based research reagents of outstanding quality to the global scientific community.
sdAb is the smallest known antigen binding fragment, leaving an indelible mark on biomedicine. However, its high production cost limits the wide application of sdAb globally. Jotbody, the first biotechnology company to offer shark sdAb discovery in Asia, has demonstrated the use of a common small shark species for the discovery and development of sdAbs at low cost and with easy operation. Jotbody also offers a na?ve library for rapid antibody discovery and camelid derived sdAb discovery for therapeutic applications.
So far, we have served several biopharma companies and have earned their strong approval. We have also developed tens of fully-validated sdAb-based research reagents and are liaising with big pharmaceutical companies on product sales.
Dr Shi Jiahai (Graduate, National University of Singapore)
Dr Yang Naibo (Graduate, Thomas Jefferson University)
Mr Lin Xiangqian (Graduate, University of Pennsylvania)
Dr Wei Likun (Alumnus, Dept. of Biomedical Sciences, CityU)
Dr Marco Pirisinu (Graduate, University of Sassari)
(Info based on the company's application form)
- CityU HK Tech 300 Angel Fund (2022)
- CityU HK Tech 300 Seed Fund (2021)
- Team Promotion Award, The 11th China Shenzhen Innovation and Entrepreneurship Competition (Semi-Final) (2022)
- Incubatee, HKSTP Incu-Bio Programme (2021)
- Team Winning Prize, The 13th Shenzhen-Hong Kong-Macao University Qualifier Area (2021)